British American Tobacco p.l.c.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BTI research report →
Range $68.1 – $68.1
Price Chart
About the company
British American Tobacco p. l. c.
- CEO
- Tadeu Luiz Marroco
- IPO
- 1980
- Employees
- 47,797
- HQ
- London, GL, GB
AI snapshot
Six angles, distilled from the data.
BTI remains in a constructive multi-month uptrend, trading above both its 50-day and 200-day moving averages. The shares are also near the upper end of the 52-week range, which points to a strong regime rather than a deep-value rebound setup.
Street sentiment is positive, with a Buy consensus and an average target of 70.37, above the recent close. Recent changes lean supportive: Goldman Sachs upgraded to Buy on 2026-11-02, while other firms have mostly reiterated existing views rather than turning more cautious.
The next print comes after a mixed recent record: one beat and one miss in the last two reported quarters. Estimates point higher, with next-year EPS at 5.22 versus 3.90 TTM, so shareholders should watch whether pricing power and mix can keep earnings on that path.
No notable insider buying or selling in recent quarters. The only recent item is a 2022 director entry marked as other, with no shares reported, which does not signal discretionary trading.
Profitability is strong, with a 82.7% gross margin, 34.7% operating margin, and 25.0% net margin. Growth is modest but positive, with revenue up 1.4% year over year, while free cash flow of 6.89 billion and a 5.26% FCF yield support the equity story.
BTI’s appeal is its cash generation and margin profile versus a typical consumer staples peer set, even as tobacco remains a mature category. At 15.77x earnings, valuation is not stretched for a high-margin defensive name, especially with the market assigning a premium target above the current price.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $124.65B
- P/E
- 15.07
- Fwd P/E
- 15.85
- PEG
- 0.14
- P/S
- 3.67
- P/B
- 1.97
- EV/EBITDA
- 10.68
- Div Yield
- 5.54%
- Gross Margin
- 82.16%
- Op Margin
- 37.06%
- Net Margin
- 25.08%
- ROE
- 13.42%
- ROIC
- 7.51%
Latest fiscal year · YoY change
- Revenue
- $25.61B-1.0%
- Gross Profit
- $21.38B-0.2%
- Op Income
- $10.00B
- Net Income
- $7.76B+153.1%
- EPS
- $3.51+156.2%
- OCF Growth
- -37.4%
- FCF Growth
- -39.2%
- 52W High
- $67.30
- 52W Low
- $52.06
- 50D MA
- $57.89
- 200D MA
- $59.24
- Beta
- 0.13
- RSI (14)
- 38
- Avg Volume
- 5.12M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BAT said H1 results were in line with expectations, with strong U.S. multi-category and Velo momentum, and raised full-year EPS guidance to the middle of its 5% to 8% range.· July 30, 2026
- H1 revenue grew 2.9%, adjusted gross profit rose 3.8%, adjusted profit from operations increased 3.5%, and adjusted diluted EPS was up 7.9% (constant currency).
- Smokeless reached 19.8% of group revenue, up 160 bps year over year, with 4.1 million more smokeless consumers over 12 months.
- New category revenue accelerated 18%, led by Modern Oral up 66%; category contribution rose 55% to GBP 269 million.
- The company expects H2 profit to be stronger, helped by AME/APMEA improvement, Fit2Win savings, and more investment in U.S. Vapor and combustibles.
- Full-year EPS guidance was upgraded to the middle of the 5% to 8% range; leverage is expected to be within 2 to 2.5x by year-end.
- BAT reiterated GBP 1.3 billion of share buybacks in 2026 and said it remains on track to generate more than GBP 50 billion of free cash flow by 2030.
Reported on a constant currency adjusted basis, group revenue increased 2.9%, adjusted gross profit rose 3.8%, adjusted profit from operations grew 3.5%, and adjusted diluted EPS increased 7.9%. New categories delivered 18% revenue growth, with Modern Oral up 66% and Vapour up 5.3%, while heated products revenue fell nearly 12%; category contribution reached GBP 269 million, up 55%. Combustibles revenue rose 2.1% with price/mix up 6.8%, while combustible volumes fell 4.7%. Group operating margin was 43.7%, up 30 bps. Adjusting items included approximately GBP 800 million primarily from U.S. trademark amortization, a GBP 370 million Fit2Win-related one-off, and a GBP 149 million credit from historical litigation settlement. For the full year, management expects net finance cost of around GBP 1.65 billion, an underlying tax rate of 24% to 25%, revenue and operating profit at the lower end of the previously guided range, and EPS growth towards the middle of the 5% to 8% range. The company also said it expects to be within its 2 to 2.5x leverage corridor by year-end.
Tadeu Marroco framed the quarter as evidence that BAT’s transformation is gaining momentum, especially in smokeless and in the U.S. multi-category portfolio. He emphasized that BAT is now the fastest-growing company in total nicotine, with Velo and Vuse strengthening leadership positions, and said the business is returning to its algorithm after a period of investment and transition. His tone was confident but disciplined, stressing that the company is investing where returns are strongest and focusing on long-term sustainable growth rather than maximizing short-term results.
Javed Iqbal highlighted that H1 results were in line with expectations on a constant currency basis, with stronger performance from the U.S. and new categories. He called out the main adjusting items: about GBP 800 million from U.S. trademark amortization, GBP 370 million of Fit2Win-related adjustments, and a GBP 149 million litigation credit, and said the group posted a 43.7% operating margin, up 30 bps. He also guided to net finance cost of around GBP 1.65 billion, a 24% to 25% tax rate, leverage within 2 to 2.5x by year-end, and full-year EPS growth in the middle of the 5% to 8% range, supported by strong cash conversion above 95% for the full year.
Analysts focused on the sustainability of U.S. Vapor enforcement tailwinds, the rollout pace and economics of Velo Max, U.S. combustibles outperformance versus the algorithm, and whether European vape weakness and market exits were complete. Management said enforcement is helping the legal Vapor market, but the bigger change should come from more level playing field and FDA prioritization guidance; Vuse flavor rollout will start in Q3 in about 25,000 outlets and then expand in Q4. On U.S. combustibles, BAT said H1 benefited from trade movements and that second-half performance should moderate closer to the algorithm as it increases investment and lapping gets tougher; on market exits in Vapor, management said most actions are already taken but some H2 impact may still remain.
The bull case from the call is that BAT’s smokeless transition is clearly gaining scale, with smokeless now nearly one-fifth of group revenue and Modern Oral/Vuse/Velo posting very strong growth. Management sounded increasingly confident that regulatory changes, especially in U.S. Vapor and global Modern Oral, can support longer-term category expansion and margin improvement.
The main risks discussed were slower-than-expected recovery in APMEA, ongoing pressure in heated products, and continued competition and illicit activity in U.S. Vapor and cigarettes. Management also said H2 will be tougher because strong U.S. inventory-driven growth will not repeat, combustibles investment will rise, and some market exits and regulatory changes will continue to weigh on reported numbers.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.9%
- Shares Outstanding
- 2.19B
- Float Shares
- 2.15B
of shares held by institutions
954 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BTI, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 30, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Sep 25, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Aug 4, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 24, 25 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jul 10, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Buy | Feb 27, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jan 13, 23 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Buy | Mar 31, 22 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Buy | Mar 29, 22 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Sell | Nov 2, 22 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Buy | Aug 23, 22 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Buy | Jul 29, 22 | Filing → |
| Virginia Ann FoxxHouse · NC05 | Buy | Jul 14, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Capital International Investors | 48.93M | ▼ 206.57K |
| Fmr LLC | 46.96M | ▲ 2.80M |
| Capital Research Global Investors | 31.91M | ▲ 1.58M |
| Gqg Partners LLC | 24.57M | ▼ 3.12M |
| Blackrock, Inc. | 20.16M | ▲ 1.01M |
| Bank Of America Corp | 10.53M | ▲ 798.14K |
| Capital World Investors | 9.75M | ▲ 12.78K |
| Jpmorgan Chase & Co | 7.97M | ▲ 2.58M |
| Morgan Stanley | 7.71M | ▲ 2.51M |
| Orbis Allan Gray Ltd | 7.39M | ▼ 320.59K |
| Wells Fargo & Company/Mn | 4.87M | ▲ 224.99K |
| Natixis Advisors, LLC | 4.48M | ▲ 329.94K |
Held by 96 ETFs
Biggest fund positions in BTI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 22 | BT DE Investments Inc. | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BTI coverage
Recent articles, reports, and earnings notes.

British American Tobacco (BTI): Smokeless Growth Meets Value
British American Tobacco is a Buy for investors seeking cash generation, income, and smokeless nicotine growth. New Category momentum is improving, but leverage and combustible volume declines remain key risks.

British American Tobacco (BTI): Smokeless Growth Is Gaining Traction
British American Tobacco is a medium-term Buy as combustibles keep generating cash while smokeless products, led by Velo, show real operating momentum. The stock looks reasonably valued with a fair value estimate of $68.

British American Tobacco p.l.c. (BTI) rises 6.5% on buybacks
British American Tobacco p.l.c. (BTI) rises sharply as buyback support, stronger New Category momentum, and a favorable defensive-sector backdrop lift sentiment. The stock’s move stands out for a low-beta tobacco name, with investors still focused on income, valuation, and capital returns.
Want a deeper read on BTI?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
The Roth IRA Mistake That Turns $4,775 a Month in Tax-Free Dividends Into a Tax Bill
247wallst.com · Nov 20
Pfizer Yields 6.25%. These 3 Dividend Stocks Pay More Than a 1-Year Treasury Bill
247wallst.com · Nov 20
Philip Morris vs. British American Tobacco: Which Tobacco Dividend Is Better for Retirees?
247wallst.com · Nov 18
British American Tobacco (NYSE:BTI) Stock Crosses Below 200 Day Moving Average – Should You Sell?
defenseworld.net · Nov 18
Cigarette Sales Keep Falling. These 2 Tobacco Stocks Still Pay 5.5% Dividends
247wallst.com · Nov 14
The Roth IRA Mistake That Turns a 61-Year-Old’s $7,425 a Month in Tax-Free Dividends Into a Tax Bill
247wallst.com · Nov 13
Two 10%+ Yields I'd Hold Through Any Market
seekingalpha.com · Nov 13
British American Tobacco: The Discount To PMI Could Narrow As Velo Grows
seekingalpha.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice